WEDNESDAY, SEPTEMBER 28, 2016

NIAID seeks therapies for rare viral diseases

The Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases (NIAID) is seeking developers for therapies and strategies for emerging and rare viral diseases.

The therapies and strategies must apply to specifically targeted patient populations with non-HIV diseases.

The targeted patient populations include transplant recipients, elderly, children, pregnant women and patients with medical needs that are not being met by current medical therapies.

The NIAID considers emerging viral diseases to be infections that recently manifested in the population; or they may have existed previously, but are only now increasing in the population or region.

Rare (also called orphan) diseases affect fewer than 200,000 people in the United States. 

The NIAID is encouraging natural history studies to determine the causes of mortality, responses to care, clinical presentation, patient variability and other factors that affect a disease’s incidence rates. 

The studies will determine the safety and efficacy of the therapies, the validation of surrogate and biomarkers, and exposure and exposure-response strategies to optimize the therapies.

Interested candidates are required to have documentation that verifies their expertise in clinical research about the proposed patient populations.

Proposals must be submitted by May 12. More details can be found at the FedBizOpps.gov website dated Dec. 15, 2014.

Organizations in this story

National Institute of Allergy and Infectious Diseases (NIAID) 5601 Fishers Lane, MSC 9806 Bethesda, MD 20892-9806

Get notified the next time we write about National Institute of Allergy and Infectious Diseases (NIAID)!